Zoetis Inc.
ZTS Healthcare Drug Manufacturers Specialty & Generic
Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 2.48%, free cash flow grew 17.4% and total debt rose 37.5%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten; insiders bought in the last twelve months.
Follow ZTS
Zoetis Inc. (ZTS) Debt to equity
Zoetis Inc.'s debt to equity at the end of the quarter to 30 June 2026 was 2.9×, up 0.2× from fiscal 2025 (2.7×). Over the past ten years it has ranged from 1.3× (fiscal 2023) to 4.5× (fiscal 2015); the current reading is higher than 64% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 0.0× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 2.7× | 97.07% |
| FY2024 | 1.4× | 4.68% |
| FY2023 | 1.3× | (26.70%) |
| FY2022 | 1.8× | 22.98% |
| FY2021 | 1.5× | (23.50%) |
| FY2020 | 1.9× | (19.86%) |
| FY2019 | 2.4× | (19.38%) |
| FY2018 | 3.0× | 6.48% |
| FY2017 | 2.8× | (6.96%) |
| FY2016 | 3.0× | (33.20%) |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Jun 2026 | 2.9× | 2.73% |
| Mar 2026 | 2.8× | 5.67% |
| Dec 2025 | 2.6× | 102.18% |
| Sep 2025 | 1.3× | (0.96%) |
| 42 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| NBIX Neurocrine Biosciences, Inc. compare | 0.0× |
| UTHR United Therapeutics Corporation compare | 0.0× |
| RDY Dr. Reddy's Laboratories Ltd compare | 0.2× |
| HLN Haleon PLC Sponsored ADR compare | 0.5× |
| ELAN Elanco Animal Health Incorporated compare | 0.6× |
| TAK Takeda Pharmaceutical Co. compare | 0.7× |
| VTRS Viatris Inc. compare | 0.9× |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 2.1× |
| ZTS Zoetis Inc. | 2.9× |
| Drug Manufacturers Specialty & Generic industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on ZTS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement